| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imperial Cancer Research Fund Lincoln's Inn Fields, London, WC2A 3PX [F. R. B., A. L., G. A., E. M., J. A. T.]; Biogent, Josef Plateaustraat 22, [J. T.]; and Laboratory of Molecular Biology, Ledeganckstraat 35, [W. F.], B-9000 Ghent, Belgium
We have studied the activity of recombinant human tumor necrosis factor (rHuTNF) on six different human tumor xenografts derived from primary breast and bowel tumors and maintained by passage in nude mice. When 5 µg rHuTNF was given daily intratumorally to mice with established (approximately, 0.5 cm) tumors, total tumor regression was observed by 3–4 weeks in three of six xenograft lines. In a further two lines tumor stasis or significant slowing of growth was seen. This antitumor action was not accompanied by any consistent macroscopic change in the tumor such as necrosis, but histological examination revealed tumor cell degeneration and a large peritumoral infiltration of host inflammatory cells after 4–7 days therapy. In contrast to these data, little effect was seen when the same dose of rHuTNF was administered i.p. to nude mice bearing these tumors. In only two of six lines was any significant slowing of tumor growth seen. A 5-fold increase in the i.p. dose resulted in improved activity on only one of two xenograft lines tested. Efficacy of the i.p. rHuTNF dose could, however, be enhanced by simultaneous administration of human interferon, 
or 
. No obvious signs of toxicity were observed at all rHuTNF doses administered and weights of control and treated mice at the end of the experiments were comparable.
1 Supported by Biogen S. A. Geneva.
Received 12/26/85. Revised 3/10/86. Accepted 4/16/86.
This article has been cited by other articles:
|
|
 |
|
  S. N. Karagiannis, M. G. Bracher, J. Hunt, N. McCloskey, R. L. Beavil, A. J. Beavil, D. J. Fear, R. G. Thompson, N. East, F. Burke, et al. IgE-Antibody-Dependent Immunotherapy of Solid Tumors: Cytotoxic and Phagocytic Mechanisms of Eradication of Ovarian Cancer Cells J. Immunol., September 1, 2007; 179(5): 2832 - 2843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. McLoughlin, T. M. McCarty, C. Cunningham, V. Clark, N. Senzer, J. Nemunaitis, and J. A. Kuhn TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor {alpha}, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up Ann. Surg. Oncol., October 1, 2005; 12(10): 825 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Bellnier, S. O. Gollnick, S. H. Camacho, W. R. Greco, and R. T. Cheney Treatment with the Tumor Necrosis Factor-{alpha}-Inducing Drug 5,6-Dimethylxanthenone-4-Acetic Acid Enhances the Antitumor Activity of the Photodynamic Therapy of RIF-1 Mouse Tumors Cancer Res., November 15, 2003; 63(22): 7584 - 7590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Schotte, G. Van Loo, I. Carpentier, P. Vandenabeele, and R. Beyaert Lithium Sensitizes Tumor Cells in an NF-kappa B-independent Way to Caspase Activation and Apoptosis Induced by Tumor Necrosis Factor (TNF). EVIDENCE FOR A ROLE OF THE TNF RECEPTOR-ASSOCIATED DEATH DOMAIN PROTEIN J. Biol. Chem., July 6, 2001; 276(28): 25939 - 25945. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
